Trk-IN-2
Trk-IN-2 is an orally active pan-Trk kinase inhibitor with an TrkA IC50 of 9 nM. Trk-IN-2 exhibits pharmacodynamic effects in rat models of inflammatory pain and neuropathic pain.Trk-IN-2 can be used for the research of inflammatory pain, neuropathic pain.
For research use only. We do not sell to patients.
- CAS No.: 1614229-04-7
- Formula: C24H24N10O
- Molecular Weight:468.53
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| U2OS | IC50 |
7 nM
Compound: 11
|
Inhibition of human TrkA expressed in human U2OS cells assessed as inhibition of NGF-induced maximum response after 1 hr by beta-galactosidase assay
Inhibition of human TrkA expressed in human U2OS cells assessed as inhibition of NGF-induced maximum response after 1 hr by beta-galactosidase assay
|
[PMID: 24914455] |
In Vitro
Chemical Information
-
CAS No. 1614229-04-7
-
Molecular Weight 468.53
-
Formula C24H24N10O
-
SMILES
O=C(NC1=CC(=NN1C=2C=NC=CC2)C(C)(C)C)CN3N=NC(=C3)C=4C=NC(=CC4)N5C=NC=C5
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Formalin-Induced Paw Inflammation/Nociceptive Inflammation
The formalin-induced paw inflammation/nociceptive test is a chemical persistent pain model in rodents in which subcutaneous injection of formalin into the hind paw produces spontaneous nocifensive behaviors such as flinching and licking. The response is classically biphasic, consisting of an early acute phase (Phase I) reflecting direct activation of peripheral nociceptors (particularly C-fiber afferents), followed by a later prolonged phase (Phase II) associated with central sensitization in the spinal dorsal horn driven by sustained afferent input and inflammatory signaling. This model is widely used to evaluate analgesic and anti-inflammatory interventions because it captures both peripheral nociception and central sensitization processes within a single assay system.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)